<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="3-part\PMC7077299\results\search\disease\results.xml">
  <result pre="Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Although seasonal" exact="influenza" post="vaccines block most predominant influenza types and subtypes, humans"/>
  <result pre="license (http://creativecommons.org/licenses/by/4.0/). Abstract Although seasonal influenza vaccines block most predominant" exact="influenza" post="types and subtypes, humans still remain vulnerable to waves"/>
  <result pre="remain vulnerable to waves of seasonal and new potential pandemic" exact="influenza" post="viruses for which no immunity may exist because of"/>
  <result pre="cells (KPF1-HEK) with broad and potent neutralizing activity against H1N1" exact="influenza" post="A viruses (IAV) in vitro, and prophylactic and therapeutic"/>
  <result pre="Collectively, this study demonstrated, for the first time, a plant-produced" exact="influenza" post="hMAb with in vitro and in vivo activity against"/>
  <result pre="influenza hMAb with in vitro and in vivo activity against" exact="influenza" post="virus. Because of the many advantages of plant-produced hMAbs,"/>
  <result pre="strategy for the production of immunotherapeutics for the treatment of" exact="influenza" post="viral infections, including emerging seasonal and/or pandemic strains. orthomyxovirus"/>
  <result pre="influenza viral infections, including emerging seasonal and/or pandemic strains. orthomyxovirus" exact="influenza" post="virus antivirals plantibody prophylactic therapeutic monoclonal antibody antibody treatment"/>
  <result pre="members of the Orthomyxoviridae family and are responsible for severe" exact="respiratory disease" post="in humans [1]. Influenza viruses cause both seasonal epidemics"/>
  <result pre="[2]. Although Food and Drug Administration (FDA)-licensed inactivated and live-attenuated" exact="influenza" post="vaccines have been used for over seventy years, yearly"/>
  <result pre="vaccines have been used for over seventy years, yearly seasonal" exact="influenza" post="viral infections are still responsible for an estimated of"/>
  <result pre="and H15) subtypes [15,16,19]. Currently, H1N1 and H3N2 IAV and" exact="influenza" post="B viruses (IBV) are circulating in the human population"/>
  <result pre="circulating in the human population and are responsible for seasonal" exact="influenza" post="[1,3]. Among the different influenza viruses, H1N1 IAVs are"/>
  <result pre="and are responsible for seasonal influenza [1,3]. Among the different" exact="influenza" post="viruses, H1N1 IAVs are the most important subtype and"/>
  <result pre="antivirals are available for the prevention and treatment, respectively, of" exact="influenza" post="viral infections in humans. Influenza vaccines contain viral antigens"/>
  <result pre="and are provided as inactivated or live-attenuated forms. However, although" exact="influenza" post="vaccines are able to induce immunity, they have several"/>
  <result pre="major classes of drugs are FDA-approved for the treatment of" exact="influenza" post="infections: NA inhibitors (oseltamivir, zanamivirm and peramivir), matrix protein"/>
  <result pre="acid (PA) endonuclease inhibitors (Baloxavir, marboxil, or Xofluza) [1,10]. However," exact="influenza" post="antiviral drugs have several limitations, including the lack of"/>
  <result pre="to find alternative approaches for the prevention and treatment of" exact="influenza" post="infections in humans. Since 1990, plants have been considered"/>
  <result pre="Hepatitis B virus, HBV; Human immunodeficiency virus, HIV; Porcine epidemic" exact="diarrhea" post="virus, PEDV; Rabies virus, RABV; West Nile virus, WNV)"/>
  <result pre="date, plantibodies have not been used for the treatment of" exact="influenza" post="viral infections. In a recent study, we described that"/>
  <result pre="in vitro and prophylactic and therapeutic activity in mice against" exact="influenza" post="H1N1 IAV [47]. In this study, we demonstrated that"/>
  <result pre="prevent viral transmission in the well-established guinea pig model of" exact="influenza" post="virus infection. Altogether, our results demonstrate, for the first"/>
  <result pre="time, the feasibility of using plantibodies for the treatment of" exact="influenza" post="viral infections in humans. 2. Materials and Methods 2.1."/>
  <result pre="37 °C in a 5% CO2 atmosphere [19]. Wild-type (WT)" exact="influenza" post="viruses A/Brisbane/59/2007 H1N1 (Brisbane/H1N1), A/ California/04/2009 H1N1 (pH1N1), A/New"/>
  <result pre="are the most effective methods available to prevent and/or control" exact="influenza" post="viral infections. However, influenza vaccines require at least 2"/>
  <result pre="methods available to prevent and/or control influenza viral infections. However," exact="influenza" post="vaccines require at least 2 weeks after administration to"/>
  <result pre="possessed similar in vitro properties to KPF1-HEK hMAb and prevented" exact="influenza" post="infection and transmission in guinea pigs. KPF1-Antx was produced"/>
  <result pre="first study demonstrating the ability of plantibodies to protect against" exact="influenza" post="viral infections. Concerns exist that plantibodies can be immunogenic"/>
  <result pre="Follow-up studies to directly and extensively compare mammalian-produced to plant-produced" exact="influenza" post="specific antibodies for the impact of potential N-glycan differences"/>
  <result pre="a plant-produced hMAb for the prophylactic and therapeutic treatment of" exact="influenza" post="infections. Plant-produced hMAbs could represent an excellent option for"/>
  <result pre="represent an excellent option for the treatment and control of" exact="influenza" post="viruses against which vaccines are not effective (e.g., seasonal)"/>
  <result pre="2.LiK.S.GuanY.WangJ.SmithG.J.XuK.M.DuanL.RahardjoA.P.PuthavathanaP.BuranathaiC.NguyenT.D.et al.Genesis of a highly pathogenic and potentially pandemic H5N1" exact="influenza" post="virus in eastern AsiaNature200443020921310.1038/nature0274615241415 3.BarrI.G.McCauleyJ.CoxN.DanielsR.EngelhardtO.G.FukudaK.GrohmannG.HayA.KelsoA.KlimovA.et al.Writing Committee of the"/>
  <result pre="Vaccine Composition, f. Epidemiological, antigenic and genetic characteristics of seasonal" exact="influenza" post="A(H1N1), A(H3N2) and B influenza viruses: Basis for the"/>
  <result pre="and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B" exact="influenza" post="viruses: Basis for the WHO recommendation on the composition"/>
  <result pre="viruses: Basis for the WHO recommendation on the composition of" exact="influenza" post="vaccines for use in the 2009–2010 northern hemisphere seasonVaccine2010281156116720004635"/>
  <result pre="northern hemisphere seasonVaccine2010281156116720004635 4.ClarkA.M.DeDiegoM.L.AndersonC.S.WangJ.YangH.NogalesA.Martinez-SobridoL.ZandM.S.SangsterM.Y.TophamD.J.Antigenicity of the 2015–2016 seasonal H1N1 human" exact="influenza" post="virus HA and NA proteinsPLoS ONE201712e018826710.1371/journal.pone.018826729145498 5.FedericiC.CavazzaM.CostaF.JommiC.Health care costs"/>
  <result pre="countries: A systematic reviewPLoS ONE201813e020278710.1371/journal.pone.020278730192781 6.MolinariN.A.Ortega-SanchezI.R.MessonnierM.L.ThompsonW.W.WortleyP.M.WeintraubE.BridgesC.B.The annual impact of seasonal" exact="influenza" post="in the US: Measuring disease burden and costsVaccine2007255086509610.1016/j.vaccine.2007.03.04617544181 7.NeumannG.KawaokaY.Transmission"/>
  <result pre="in the US: Measuring disease burden and costsVaccine2007255086509610.1016/j.vaccine.2007.03.04617544181 7.NeumannG.KawaokaY.Transmission of" exact="influenza" post="A virusesVirology2015479–48023424610.1016/j.virol.2015.03.009 8.HerfstS.ImaiM.KawaokaY.FouchierR.A.Avian influenza virus transmission to mammalsCurr. Top."/>
  <result pre="disease burden and costsVaccine2007255086509610.1016/j.vaccine.2007.03.04617544181 7.NeumannG.KawaokaY.Transmission of influenza A virusesVirology2015479–48023424610.1016/j.virol.2015.03.009 8.HerfstS.ImaiM.KawaokaY.FouchierR.A.Avian" exact="influenza" post="virus transmission to mammalsCurr. Top. Microbiol. Immunol.201438513715525048542 9.De ClercqE.Antiviral"/>
  <result pre="to mammalsCurr. Top. Microbiol. Immunol.201438513715525048542 9.De ClercqE.Antiviral agents active against" exact="influenza" post="A virusesNat. Rev. Drug Discov.200651015102510.1038/nrd217517139286 10.MifsudE.J.HaydenF.G.HurtA.C.Antivirals targeting the polymerase"/>
  <result pre="virusesNat. Rev. Drug Discov.200651015102510.1038/nrd217517139286 10.MifsudE.J.HaydenF.G.HurtA.C.Antivirals targeting the polymerase complex of" exact="influenza" post="virusesAntiviral Res.201916910454510.1016/j.antiviral.2019.10454531247246 11.O’HanlonR.ShawM.L.Baloxavir marboxil: The new influenza drug on"/>
  <result pre="polymerase complex of influenza virusesAntiviral Res.201916910454510.1016/j.antiviral.2019.10454531247246 11.O’HanlonR.ShawM.L.Baloxavir marboxil: The new" exact="influenza" post="drug on the marketCurr. Opin. Virol.201935141810.1016/j.coviro.2019.01.00630852344 12.SuS.FuX.LiG.KerlinF.VeitM.Novel Influenza D"/>
  <result pre="The acquisition of new host ranges by canine parvovirus and" exact="influenza" post="A virusesAnnu Rev. Microbiol.20055955358610.1146/annurev.micro.59.030804.12105916153179 16.ParrishC.R.MurciaP.R.HolmesE.C.Influenza virus reservoirs and intermediate"/>
  <result pre="reservoirs and intermediate hosts: Dogs, horses, and new possibilities for" exact="influenza" post="virus exposure of humansJ. Virol.2015892990299410.1128/JVI.03146-1425540375 17.TongS.ZhuX.LiY.ShiM.ZhangJ.BourgeoisM.YangH.ChenX.RecuencoS.GomezJ.et al.New world bats"/>
  <result pre="exposure of humansJ. Virol.2015892990299410.1128/JVI.03146-1425540375 17.TongS.ZhuX.LiY.ShiM.ZhangJ.BourgeoisM.YangH.ChenX.RecuencoS.GomezJ.et al.New world bats harbor diverse" exact="influenza" post="A virusesPLoS Pathog.20139e100365710.1371/journal.ppat.100365724130481 18.TongS.LiY.RivaillerP.ConrardyC.CastilloD.A.ChenL.M.RecuencoS.EllisonJ.A.DavisC.T.YorkI.A.et al.A distinct lineage of influenza"/>
  <result pre="diverse influenza A virusesPLoS Pathog.20139e100365710.1371/journal.ppat.100365724130481 18.TongS.LiY.RivaillerP.ConrardyC.CastilloD.A.ChenL.M.RecuencoS.EllisonJ.A.DavisC.T.YorkI.A.et al.A distinct lineage of" exact="influenza" post="A virus from batsProc. Natl. Acad. Sci. USA20121094269427410.1073/pnas.111620010922371588 19.NogalesA.PiepenbrinkM.S.WangJ.OrtegaS.BasuM.FucileC.F.TreanorJ.J.RosenbergA.F.ZandM.S.KeeferM.C.et"/>
  <result pre="of Influenza VaccinesInt. J. Mol. Sci.2016182010.3390/ijms18010020 23.TakashitaE.KawakamiC.MoritaH.OgawaR.FujisakiS.ShirakuraM.MiuraH.NakamuraK.KishidaN.KuwaharaT.[], et al.Detection of" exact="influenza" post="A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent"/>
  <result pre="December 2018Euro. Surveill.20192410.2807/1560-7917.ES.2019.24.3.180069830670142 24.EarhartK.C.ElsayedN.M.SaadM.D.GubarevaL.V.NayelA.DeydeV.M.AbdelsattarA.AbdelghaniA.S.BoyntonB.R.MansourM.M.et al.Oseltamivir resistance mutation N294S in human" exact="influenza" post="A(H5N1) virus in EgyptJ. Infect. Public Health20092748010.1016/j.jiph.2009.04.00420701864 25.OmotoS.SperanziniV.HashimotoT.NoshiT.YamaguchiH.KawaiM.KawaguchiK.UeharaT.ShishidoT.NaitoA.et al.Characterization"/>
  <result pre="A(H5N1) virus in EgyptJ. Infect. Public Health20092748010.1016/j.jiph.2009.04.00420701864 25.OmotoS.SperanziniV.HashimotoT.NoshiT.YamaguchiH.KawaiM.KawaguchiK.UeharaT.ShishidoT.NaitoA.et al.Characterization of" exact="influenza" post="virus variants induced by treatment with the endonuclease inhibitor"/>
  <result pre="oseltamivir: An oral antiviral for the treatment and prophylaxis of" exact="influenza" post="in diverse populationsJ. Antimicrob. Chemother.201065ii5ii1010.1093/jac/dkq01520215135 28.HoradamV.W.SharpJ.G.SmilackJ.D.McAnalleyB.H.GarriottJ.C.StephensM.K.PratiR.C.BraterD.C.Pharmacokinetics of amantadine hydrochloride"/>
  <result pre="Natl. Acad. Sci. USA2012109180301803510.1073/pnas.121370910923071322 47.NogalesA.Avila-PerezG.Rangel-MorenoJ.ChiemK.DeDiegoM.L.Martinez-SobridoL.A novel fluorescent and bioluminescent Bi-Reporter" exact="influenza" post="A virus (BIRFLU) to evaluate viral infectionsJ. Virol.201993e00032-1910.1128/JVI.00032-1930867298 48.NogalesA.BakerS.F.Martinez-SobridoL.Replication-competent"/>
  <result pre="influenza A virus (BIRFLU) to evaluate viral infectionsJ. Virol.201993e00032-1910.1128/JVI.00032-1930867298 48.NogalesA.BakerS.F.Martinez-SobridoL.Replication-competent" exact="influenza" post="A viruses expressing a red fluorescent proteinVirology201547620621610.1016/j.virol.2014.12.00625553516 49.NogalesA.RodriguezL.DeDiegoM.L.TophamD.J.Martinez-SobridoL.Interplay of"/>
  <result pre="of Laboratory Animals8th ed.National Academies PressWashington, DC, USA2011 55.GaugerP.C.LovingC.L.KhuranaS.LorussoA.PerezD.R.KehrliM.E.Jr.RothJ.A.GoldingH.VincentA.L.Live attenuated" exact="influenza" post="A virus vaccine protects against A(H1N1)pdm09 heterologous challenge without"/>
  <result pre="Brisbane/H1N1, pH1N1, NC/H1N1, PR8/H1N1, WI/H1N1, or GA/H1N1; and Brisbane/ H3N2" exact="influenza" post="A virus; or mock infected. At 12 h p.i.,"/>
 </snippets>
</snippetsTree>
